Skip to main content

Market Overview

Endo Pharmaceuticals (ENDP) to commercialize FORTESTA(TM) with ProStrakan

Ben Zinga

August 26, 2009 9:05am Comments

Endo Pharmaceuticals (Nasdaq: ENDP) signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View Comments and Join the Discussion!

View the discussion thread.

1	BUD, AMZN: Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Invest...
2	NOW, INFY: SoundHound AI Gains 27% in a Month: Should You Buy?
3	Paul Krugman Warns Of Pre-Recession Signals, Says 'Sahm R...
4	TEVA: Teva Beats Q2 Estimates, Raises Annual Outlook On Strong G...
5	Mohamed El-Erian Notes Markets Interpret Fed Chair Powell&...
6	Fed Chair Jerome Powell's Stance On 'Sahm Rule&#...
7	'Dr. Doom' Nouriel Roubini Plans To Launch His F...

1	AMZN, TSLA: Amazon, Apple, Block, Intel, Tesla: Why These 5 Stocks Are On Investor...
2	Joe Biden And Kamala Harris Greet Evan Gershkovich And Paul Whelan At...
3	AAPL: Tim Cook Remains Optimistic About Greater China Market Despite 6.5...
4	UST, $LUNA: US Loses Out To South Korea Over Extradition Of Terrafor...
5	Reddit Co-Founder And Serena Williams Husband Alexis Oha...
6	TSLA: Tesla's Autopilot System Failed In Deadly 2022...
7	$BTC, MSTR: Michael Saylor Hails Trump's 'Ne...